Literature DB >> 9372038

Can Creutzfeldt-Jakob disease be transmitted by transfusion?

P Brown1.   

Abstract

The transmissible agent of Creutzfeldt-Jakob disease, a dementing neurodegenerative disorder, is present in many tissues of the body, even though its pathologic consequences are confined to the brain. Experimental animal models of the disease have shown that blood (most probably the leukocyte component) can be infectious in both the clinical and preclinical incubation stages of the disease, and there are also a few reported isolations of the agent from whole blood, buffy coats, or serum from humans with Creutzfeldt-Jakob disease. Despite this potential for blood-borne iatrogenic infection, epidemiologic studies do not support the contention that the administration of blood, blood components, or blood derivatives transmits the disease; in particular, not one of nearly 2000 patients who have been studied during the past two decades has been shown to have acquired the disease from a blood donor who later died of Creutzfeldt-Jakob disease. This fact does not diminish our responsibility to preclude such an occurrence from happening in the future, and will require an unremitting effort to screen from the blood donor population all individuals with a higher than average risk of harboring the infectious agent; namely, donors with neurologic disease, a family history of neurologic disease, or a history of events that have been identified as leading to iatrogenic Creutzfeldt-Jakob disease, such as neurosurgical procedures involving dura mater homografts or treatment with native pituitary hormones.

Entities:  

Mesh:

Year:  1995        PMID: 9372038     DOI: 10.1097/00062752-199502060-00012

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  12 in total

Review 1.  Molecular neurology of prion disease.

Authors:  J Collinge
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-07       Impact factor: 10.154

Review 2.  Safety of IGIV therapy and infusion-related adverse events.

Authors:  Mark Ballow
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

3.  Transmissible spongiform encephalopathies and tissue cell culture.

Authors:  D N Galbraith
Journal:  Cytotechnology       Date:  2002-07       Impact factor: 2.058

Review 4.  Management of notifications of donors with Creutzfeldt-Jakob disease (post-donation information).

Authors:  Gabriele Calizzani; Stefania Vaglio; Vito Vetrugno; Marisa Delbò; Luca Pani; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2013-10-02       Impact factor: 3.443

5.  BSE safety standards: An evaluation of public health policies of Japan, Europe, and USA.

Authors:  Gino C Matibag; Manabu Igarashi; Hiko Tamashiro
Journal:  Environ Health Prev Med       Date:  2005-09       Impact factor: 3.674

6.  B cells and platelets harbor prion infectivity in the blood of deer infected with chronic wasting disease.

Authors:  Candace K Mathiason; Jeanette Hayes-Klug; Sheila A Hays; Jenny Powers; David A Osborn; Sallie J Dahmes; Karl V Miller; Robert J Warren; Gary L Mason; Glenn C Telling; Alan J Young; Edward A Hoover
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

7.  Clinical experience with Flebogamma 5% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease.

Authors:  M Ballow
Journal:  Clin Exp Immunol       Date:  2009-09       Impact factor: 4.330

8.  Problems with precaution: the transfusion medicine experience.

Authors:  Kumanan Wilson; Katherine M Atkinson; Dean A Fergusson; Adalsteinn Brown; Alan Forster; Malia S Q Murphy; Alan T Tinmouth; Jennifer Keelan
Journal:  J Risk Res       Date:  2017-07-29

9.  Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns.

Authors:  P Brown; R G Will; R Bradley; D M Asher; L Detwiler
Journal:  Emerg Infect Dis       Date:  2001 Jan-Feb       Impact factor: 6.883

Review 10.  Insights into the management of emerging infections: regulating variant Creutzfeldt-Jakob disease transfusion risk in the UK and the US.

Authors:  Maya L Ponte
Journal:  PLoS Med       Date:  2006-10       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.